A Phase 1 First in Human, Randomized, Double Blind, Sponsor Open, Placebo-Controlled, Single- and Multiple Dose Escalation, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis